PL02.12 Ivonescimab vs Placebo Plus Chemo, Phase 3 in Patients with EGFR+ NSCLC Progressed with 3rd gen EGFR-TKI Treatment: HARMONi
J.W. Goldman(UCLA Health), A. Passaro(European Institute of Oncology), J. Laskin(BC Cancer Foundation), D. Rodrigues-Abreu(Universidad de Las Palmas de Gran Canaria), Antonio Calles(Hospital General Universitario Gregorio Marañón), L. Bazhenova(UC San Diego Health System), Giuseppe Lo Russo(Fondazione IRCCS Istituto Nazionale dei Tumori), N. Leighl(Princess Margaret Cancer Centre), F. Cappuzzo(National Cancer Institute), N. Girard(Institut Curie), S. Popat(Royal Marsden Hospital), Weizhen Fang(Sun Yat-sen University Cancer Center), Ying Luo(Hunan Cancer Hospital), Rong Yang, Wenyu Li(Zhongshan Hospital), Junmin Li(Vyne Therapeutics (United States)), Lori Styles(Vyne Therapeutics (United States)), Bruce Thompson(Vyne Therapeutics (United States)), Lin Zhang(Sun Yat-sen University Cancer Center), X. Le(The University of Texas MD Anderson Cancer Center)
Cited by 9
Abstract
Related Papers
No related papers found
Powered by citation graph analysis